Discovery of novel hypermethylated genesin prostate cancer using genomic CpG island microarrays

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Kron, Ken ^a,b   Pethe, Vaijayanti ^a   Briollais, Laurent ^a   Sadikovic, Bekim ^c   Ozcelik, Hilmi ^a   Sunderji, Alia ^a,b   Venkateswaran, Vasundra ^d   Pinthus, Jehonathan ^e   Fleshner, Neil ^b   van der Kwast, Theodorus ^f   Bapat, Bharati ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HOX PROTEIN; OSTEOGENIC PROTEIN 1; TRANSCRIPTION FACTOR HOXD3; UNCLASSIFIED DRUG; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; BMP7 PROTEIN, HUMAN; DRUG DERIVATIVE; HOMEODOMAIN PROTEIN; HOXD3 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; CPG ISLAND; DISEASE MARKER; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; PROSTATE CANCER; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; VALIDATION PROCESS; DNA MICROARRAY; DRUG EFFECT; GENE SILENCING; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; MALE; METHODOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MORPHOGENETIC PROTEIN 7; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HOMEODOMAIN PROTEINS; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS;

EID: 63049098369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004830     Document Type: Article

References (44)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10-30.
2. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125-128.
3. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448: 111-118.
4. Ting AH, McGarvey KM, Baylin SB (2006) The cancer epigenome-components and functional correlates. Genes Dev 20: 3215-3231.
5. Hadnagy A, Beaulieu R, Balicki D (2008) Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 7: 740-748.
6. Lafon-Hughes L, Di Tomaso MV, Mendez-Acuna L, Martinez-Lopez W (2008) Chromatin-remodelling mechanisms in cancer. Mutat Res 658: 191-214.
7. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
8. Clark SJ, Harrison J, Molloy PL (1997) Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 195: 67-71.
9. Yu F, Thiesen J, Stratling WH (2000) Histone deacetylase-independent transcriptional repression by methyl-CpG-binding protein 2. Nucleic Acids Res 28: 2201-2206.
10. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
11. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266.
12. Li LC, Carroll PR, Dahiya R (2005) Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97: 103-115.
13. Meiers I, Shanks JH, Bostwick DG (2007) Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology 39: 299-304.
14. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, et al. (1999) Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 18: 1313-1324.
15. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV, Laktionov PP (2008) Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci 1137: 222-225.
16. Suzuki MM, Bird A (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9: 465-476.
17. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, et al. (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8: 514-519.
18. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, et al. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530.
19. Ye L, Lewis-Russell JM, Sanders AJ, Kynaston H, Jiang WG (2008) HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urol Oncol 26: 190-197.
20. Taniguchi Y, Komatsu N, Moriuchi T (1995) Overexpression of the HOX4A (HOXD3) homeobox gene in human erythroleukemia HEL cells results in altered adhesive properties. Blood 85: 2786-2794.
21. Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH, et al. (2001) Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 61: 8375-8380.
22. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371.
23. Smyth GK (2005) Limma: linear models for microarray data. Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds. New York: Springer. pp. 397-420.
24. Yang YH, Dudoit S, Luu P, Speed TP (2001) Normalization for cDNA microarry data; San Jose, CA, USA: SPIE. pp. 141-152.
25. Sadikovic B, Andrews J, Carter D, Robinson J, Rodenhiser DI (2008) Genome-wide H3K9 histone acetylation profiles are altered in benzopyrene-treated MCF7 breast cancer cells. J Biol Chem 283: 4051-4060.
26. Sadikovic B, Yoshimoto M, Al-Romaih K, Maire G, Zielenska M, et al. (2008) In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS ONE 3: e2834.
27. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, et al. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
28. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, et al. (2007) Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 104: 5527-5532.
29. Rodriguez BA, Cheng AS, Yan PS, Potter D, Agosto-Perez FJ, et al. (2008) Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 29: 1459-1465.
30. Suh ER, Ha CS, Rankin EB, Toyota M, Traber PG (2002) DNA methylation down-regulates CDX1 gene expression in colorectal cancer cell lines. J Biol Chem 277: 35795-35800.
31. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, et al. (2007) BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171: 1047-1057.
32. Ordway JM, Bedell JA, Citek RW, Nunberg A, Garrido A, et al. (2006) Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis 27: 2409-2423.
33. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T (2006) Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 97: 64-71.
34. Rauch T, Li H, Wu X, Pfeifer GP (2006) MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 66: 7939-7947.
35. Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22: 233-241.
36. Masuda H, Fukabori Y, Nakano K, Takezawa Y, T CS, et al. (2003) Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54: 268-274.
37. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, et al. (2008) Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 68: 152-160.
38. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, et al. (2007) Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 13: 3796-3802.
39. Miyazaki YJ, Hamada J, Tada M, Furuuchi K, Takahashi Y, et al. (2002) HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells. Oncogene 21: 798-808.
40. Massague J (2008) TGFbeta in Cancer. Cell 134: 215-230.
41. Hamada J, Omatsu T, Okada F, Furuuchi K, Okubo Y, et al. (2001) Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. Int J Cancer 93: 516-525.
42. Okubo Y, Hamada J, Takahashi Y, Tada M, Tsutsumida A, et al. (2002) Transduction of HOXD3-antisense into human melanoma cells results in decreased invasive and motile activities. Clin Exp Metastasis 19: 503-511.
43. Takahashi Y, Hamada J, Murakawa K, Takada M, Tada M, et al. (2004) Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res 293: 144-153.
44. Attwood JT, Yung RL, Richardson BC (2002) DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 59: 241-257.